In this study, we find that SATB1 is also highly expressed in ovarian cancer cells and lymphoma cells, and importantly SATB1-specific T cells can recognize and kill these cancer cells, suggesting that identification of SATB1 as a tumor antigen has important implications for the development of potentially therapeutic vaccines against ovarian cancer, lymphoma and other types of cancer as well. This evidence concerns the gene SATB1 and ovarian cancer.